Where does Trevi Therapeutics, Inc.'s income statement data come from?

Every line is extracted from Trevi Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	FY'25	FY'24	FY'23	FY'22
Research and development	$33.48M-15.0%	$39.38M+66.3%	$23.68M+19.4%	$19.83M-13.7%
General and administrative	$15.85M+30.5%	$12.15M+18.6%	$10.24M+1.7%	$10.07M+6.1%
Compensation and benefits	$5.19M+44.5%	$3.59M+65.2%	$2.17M-6.7%	$2.33M-8.5%
Depreciation and amortization	$144K-2.0%	$147K+19.5%	$123K+186%	$43K—
Other operating expenses	8,843,600,000%-237,000,000%	9,080,600,000%+3,189,300,000%	5,891,300,000%+575,600,000%	5,315,700,000%-352,200,000%
Total operating expenses	$49.33M-4.3%	$51.53M+51.9%	$33.92M+13.4%	$29.91M-7.9%
Operating income	-$49.33M+4.3%	-$51.53M-51.9%	-$33.92M-13.4%	-$29.91M+7.9%
Interest income	$6.54M+81.5%	$3.6M—	——	——
Other income (expense), net	$6.51M+81.6%	$3.58M-25.8%	$4.83M+571%	$719K+148%
Net investment gains (losses)	$0—	$0—	$0—	$0—
Income before income taxes	-$42.82M+10.7%	-$47.94M-64.8%	-$29.1M+0.3%	-$29.19M+14.1%
Income tax expense	-$63K—	——	——	-$36K-71.4%
Net income	-$42.76M+10.8%	-$47.91M-64.8%	-$29.07M+0.3%	-$29.15M+14.1%
Diluted earnings per share	-$0.32+31.9%	-$0.47-62.1%	-$0.29+43.1%	-$0.51+66.0%
Basic earnings per share	-$0.32+31.9%	-$0.47-62.1%	-$0.29+43.1%	-$0.51+65.8%
Weighted-average shares, diluted	527.8M+30.7%	403.8M+2.1%	395.7M+76.8%	223.8M+166%
Weighted-average shares, basic	527.8M+30.7%	403.8M+2.1%	395.7M+76.8%	223.8M—
Accretion (Amortization) of Discounts and Premiums, Investments	$1.64M+19.8%	$1.37M-35.7%	$2.13M—	——
Share-based compensation expense related to employee stock plans	$5.19M+44.5%	$3.59M+59.7%	$2.25M-3.4%	$2.33M-8.5%
Stock options excluded as their inclusion would be anti-dilutive (in shares)	——	——	——	——
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation	-$15.18M-993%	$1.7M-91.4%	$19.81M+182%	-$24.24M—
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$42.67M+10.8%	-$47.82M-65.1%	-$28.97M+1.0%	-$29.27M+13.7%
Current Federal, State and Local, Tax Expense (Benefit)	-$64K-113%	-$30K+6.3%	-$32K+11.1%	-$36K-71.4%
Current State And Local Tax Expense Benefit	-$64K-113%	-$30K+6.3%	-$32K+11.1%	-$36K-71.4%
Total net securities (losses)	$0—	$0—	$0—	$0—
Dividends, Common Stock, Cash	$0—	$0—	$0—	——
Effective tax rates	$00.0%	$00.0%	$00.0%	$00.0%
Income taxes at U.S. statutory rate of 21%	——	——	——	——
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent	——	——	——	——
Other	$0—	$0—	——	——
Share-based compensation	——	——	——	——
State income taxes – net of federal income tax benefit	——	——	——	——
Effective Income Tax Rate Reconciliation Tax Credits Research	——	——	——	——
Finance Lease Principal Payments	$11K-91.3%	$127K+32.3%	$96K—	——
Income Tax Credits Exchanged For Cash	$33K+3.1%	$32K-41.8%	$55K—	——
State taxes	-$33K-3.1%	-$32K—	——	——
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount	$8.96M-13.5%	$10.36M—	——	——
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount	-$8.99M+10.7%	-$10.07M—	——	——
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount	$14K+193%	-$15K—	——	——
Share-based compensation	$1.2M+34.5%	$895K—	——	——
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount	-$69K+15.9%	-$82K—	——	——
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount	$1.18M+5.8%	$1.12M—	——	$5.4M—
Income Taxes Paid, Net	-$33K-3.1%	-$32K—	——	——
Accounts payable	——	$1.61M—	——	$9K—
Accrued liabilities	——	——	$52K+108%	-$639K-290%
Increase (Decrease) in Prepaid Expense and Other Assets	——	-$2.74M-193%	$2.94M—	——
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	$121.01M+96.8%	$61.48M—	——	$111.31M+436%
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation	-$94.11M—	——	$59.43M—	——
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	-$42.09M-10.0%	-$38.26M-20.6%	-$31.71M-12.5%	-$28.18M+2.7%
Number of operating segments	——	——	——	1—
Number of reportable segments	——	——	——	1—
Offering Costs Included In Accrued Expenses	——	$233K—	——	$15K-63.4%
Operating lease right-of-use assets amortization expense	$437K-5.0%	$460K—	——	——
Unrealized gains (losses) on available-for-sale securities	$87K—	——	$93K—	——
Other income, net (Note 6)	-$30K—	——	$472K+63.3%	$289K+177%
Payments Of Stock Issuance Costs	$809K—	——	$258K+9.3%	$236K-43.8%
Payments to Acquire Marketable Securities	$170.66M+73.3%	$98.46M—	——	——
Payments to Acquire Property, Plant, and Equipment	——	——	$137K—	——
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale	$76.57M-0.5%	$76.97M+10.8%	$69.5M—	——
Proceeds From Offering Net Of Commissions	$108.15M+130%	$47M—	——	——
Cash received from option exercises	$2.08M+428%	$394K+432%	$74K-46.8%	$139K—
Proceeds From Warrant Exercises	——	——	——	$11.78M+392,633%
Stock-based compensation	$5.19M+44.5%	$3.59M+65.2%	$2.17M-6.7%	$2.33M-8.5%
Weighted-average grant date fair value of stock options (in dollars per share)	——	——	——	——
Granted (in shares)	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period	——	——	——	——
Risk-free interest rates, high end of range (as a percent)	——	——	——	——
Risk-free interest rates, low end of range (as a percent)	——	——	——	——
Volatilities, high end of range (as a percent)	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period	——	——	——	——
Volatilities, low end of range (as a percent)	——	——	——	——
Intrinsic value of stock options exercised	$4.34B+1,421,867%	$305K+76.3%	$173K+424%	$33K—
Options canceled (in dollars per share)	——	——	——	——
Granted (in shares)	——	——	——	——
Options forfeited/expired (in dollars per share)	——	——	——	——
Exercised (in shares)	——	——	——	——
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1	$4.5M+87.5%	$2.4M+41.2%	$1.7M-41.4%	$2.9M+20.8%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period	——	——	——	——
Issuance of common stock in connection with the Spin-Off and reclassification of net parent investment	$107.42M+130%	$46.77M—	——	——
Stock Issued During Period, Value, Stock Options Exercised	$2.08M+429%	$393K+438%	$73K—	——
Stock Issued During Period Value Stock Warrant Exercise	——	——	——	——
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$11.2M-13.2%	$12.9M+53.6%	$8.4M0.0%	$8.4M-15.2%
Write Off Of Deferred Offering Costs	$26K—	——	$390K—	——
EBIT	-$49.33M+4.3%	-$51.53M-51.9%	-$33.92M-13.4%	-$29.91M+7.9%
EBITDA	-$49.18M+4.3%	-$51.38M-52.0%	-$33.8M-13.2%	-$29.86M+7.9%
EBITDA	-$49.18M+4.3%	-$51.38M-52.0%	-$33.8M-13.2%	-$29.86M+7.9%
EBIT	-$49.33M+4.3%	-$51.53M-51.9%	-$33.92M-13.4%	-$29.91M+7.9%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Trevi Therapeutics, Inc.'s income statement data come from?: Every line is extracted from Trevi Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.